Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Your Article Summary
See Latest ArticlesActivity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Robertson JFR et al. – Fulvestrant may be a suitable treatment option in extensively pre-treated patients with HER2-positive, hormone receptor-positive ABC.
Methods- Clinical experience data from 10 treatment centres pooled
- Postmenopausal patients with predominantly hormone receptor-positive and HER2-positive disease included
- Clinical benefit (CB) was defined as the proportion of patients achieving a response to treatment (partial or complete) or stable disease lasting ≥ 6 months
- Data for 102 patients analysed
- Fulvestrant resulted in overall CB rate of 42% (43/101) in HER2-positive patients and 40% (25/63) in patients with visceral disease
- Median duration of treatment 14.5 months (range 6–44 months)
- Fulvestrant showed activity up to fourth line of endocrine therapy and up to seventh line of overall therapy
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells
Oncogene, 11/25/09
Adenosine A1 receptor, a target and regulator of estrogen receptor action, mediates the proliferative effects of estradiol in breast cancer
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor